Difference between revisions of "Tyrosine kinase inhibitors"
Jump to navigation
Jump to search
(redirect) |
|||
| Line 5: | Line 5: | ||
* Gefitinib (Iressa). | * Gefitinib (Iressa). | ||
* Erlotinib (Tarceva). | * Erlotinib (Tarceva). | ||
==Use== | |||
*[[Lung adenocarcinoma]]. | |||
*[[Adenosquamous carcinoma of the lung]].<ref name=pmid23769878>{{Cite journal | last1 = Song | first1 = Z. | last2 = Lin | first2 = B. | last3 = Shao | first3 = L. | last4 = Zhang | first4 = Y. | title = Therapeutic efficacy of gefitinib and erlotinib in patients with advanced lung adenosquamous carcinoma. | journal = J Chin Med Assoc | volume = 76 | issue = 9 | pages = 481-5 | month = Sep | year = 2013 | doi = 10.1016/j.jcma.2013.05.007 | PMID = 23769878 }}</ref> | |||
==See also== | ==See also== | ||
*[[Epidermal growth factor receptor inhibitors]]. | *[[Epidermal growth factor receptor inhibitors]]. | ||
*[[Cancer drugs]]. | *[[Cancer drugs]]. | ||
==References== | |||
{{Reflist|1}} | |||
[[Category:Clinical]] | [[Category:Clinical]] | ||
Revision as of 01:26, 9 April 2014
Tyrosine kinase inhibitors, abbreviated TKIs, are a group of drugs that inhibit the action of tyrosine kinases.
The category includes many cancer drugs - including:
- Imatinib (Gleevec).
- Gefitinib (Iressa).
- Erlotinib (Tarceva).
Use
See also
References
- ↑ Song, Z.; Lin, B.; Shao, L.; Zhang, Y. (Sep 2013). "Therapeutic efficacy of gefitinib and erlotinib in patients with advanced lung adenosquamous carcinoma.". J Chin Med Assoc 76 (9): 481-5. doi:10.1016/j.jcma.2013.05.007. PMID 23769878.